Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

520 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine.
García-Hernández E, González-Sánchez JL, Andrade-Manzano A, Contreras ML, Padilla S, Guzmán CC, Jiménez R, Reyes L, Morosoli G, Verde ML, Rosales R. García-Hernández E, et al. Among authors: rosales r. Cancer Gene Ther. 2006 Jun;13(6):592-7. doi: 10.1038/sj.cgt.7700937. Cancer Gene Ther. 2006. PMID: 16456551 Clinical Trial.
Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus.
Corona Gutierrez CM, Tinoco A, Navarro T, Contreras ML, Cortes RR, Calzado P, Reyes L, Posternak R, Morosoli G, Verde ML, Rosales R. Corona Gutierrez CM, et al. Among authors: rosales r. Hum Gene Ther. 2004 May;15(5):421-31. doi: 10.1089/10430340460745757. Hum Gene Ther. 2004. PMID: 15144573 Clinical Trial.
Clinical protocol. A phase II study: efficacy of the gene therapy of the MVA E2 recombinant virus in the treatment of precancerous lesions (NIC I and NIC II) associated with infection of oncogenic human papillomavirus.
Corona Gutierrez CM, Tinoco A, López Contreras M, Navarro T, Calzado P, Vargas L, Reyes L, Posternak R, Rosales R. Corona Gutierrez CM, et al. Among authors: rosales r. Hum Gene Ther. 2002 Jun 10;13(9):1127-40. doi: 10.1089/104303402753812520. Hum Gene Ther. 2002. PMID: 12067445 Clinical Trial. No abstract available.
MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study.
Albarran Y Carvajal A, de la Garza A, Cruz Quiroz BJ, Vazquez Zea E, Díaz Estrada I, Mendez Fuentez E, López Contreras M, Andrade-Manzano A, Padilla S, Varela AR, Rosales R. Albarran Y Carvajal A, et al. Among authors: rosales r. BioDrugs. 2007;21(1):47-59. doi: 10.2165/00063030-200721010-00006. BioDrugs. 2007. PMID: 17263589 Clinical Trial.
R-Ras promotes tumor growth of cervical epithelial cells.
Rincón-Arano H, Rosales R, Mora N, Rodriguez-Castañeda A, Rosales C. Rincón-Arano H, et al. Among authors: rosales r, rosales c. Cancer. 2003 Feb 1;97(3):575-85. doi: 10.1002/cncr.11093. Cancer. 2003. PMID: 12548599 Free article.
Regression of human papillomavirus intraepithelial lesions is induced by MVA E2 therapeutic vaccine.
Rosales R, López-Contreras M, Rosales C, Magallanes-Molina JR, Gonzalez-Vergara R, Arroyo-Cazarez JM, Ricardez-Arenas A, Del Follo-Valencia A, Padilla-Arriaga S, Guerrero MV, Pirez MA, Arellano-Fiore C, Villarreal F. Rosales R, et al. Among authors: rosales c. Hum Gene Ther. 2014 Dec;25(12):1035-49. doi: 10.1089/hum.2014.024. Hum Gene Ther. 2014. PMID: 25275724 Free PMC article. Clinical Trial.
520 results